Pre-emptive treatment with nilotinib after second allogeneic transplantation in a philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse

Acta Haematologica

Volumn 123, Issue 4, 2010, Pages 242-247

  Kang, Byung Woog ^a   Moon, Joon Ho ^a   Chae, Yee Soo ^a   Kim, Jong Gwang ^a   Kim, Shi Nae ^a   Sohn, Sang Kyun ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Acute lymphoblastic leukemia; Allogeneic hematopoietic stem cell transplantation; Dasatinib; Imatinib; Nilotinib; Ph+; Philadelphia chromosome

Indexed keywords

ASPARAGINASE; BCR ABL PROTEIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; HLA ANTIGEN; IMATINIB; METHOTREXATE; MITOXANTRONE; NILOTINIB; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MYELOABLATIVE CONDITIONING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PHILADELPHIA 1 CHROMOSOME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 77951939723     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314538     Document Type: Article

References (26)

1. Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, Wong RM, Negrin RS, Blume KG, Forman SJ: Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation- etoposide regimen. Blood 2008; 112: 903-909.
2. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M: Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006; 108: 1421-1423.
3. Rowe JM: Optimal management of adults with ALL. Br J Haematol 2009; 144: 468-483.
4. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes- Reese S, Gathmann I, Capdeville R, O'Brien SG: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965-1971.
5. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper- CVAD and imatinib mesylate. Blood 2004; 103: 4396-4407.
6. Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhauser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Bruck P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006; 108: 1469-1477.
7. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24: 460-466.
8. Gruber F, Mustjoki S, Porkka K: Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 2009; 145: 581-597.
9. Wassmann B, Pfeifer H, Stadler M, Bornhauser M, Bug G, Scheuring UJ, Bruck P, Stelljes M, Schwerdtfeger R, Basara N, Perz J, Bunjes D, Ledderose G, Mahlberg R, Binckebanck A, Gschaidmeier H, Hoelzer D, Ottmann OG: Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005; 106: 458-463.
10. Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ, Appelbaum FR, Radich JP: Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007; 109: 2791-2793.
11. Sohn SK, Moon JH, Cho YY, Chae YS, Kim JG, Lee KS, Hong SP, Kim SO: Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance. Leuk Lymphoma 2007; 48: 1659-1661.
12. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, Rea D, Cayuela JM, Vekemans MC, Reman O, Buzyn A, Pigneux A, Escoffre M, Chalandon Y, MacIntyre E, Lheritier V, Vernant JP, Thomas X, Ifrah N, Dombret H: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007; 109: 1408-1413.
13. Ravandi F, Kebriaei P: Philadelphia chromosome- positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23: 1043-1063, vi.
14. Ottmann OG, Pfeifer H: First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol 2009; 21(suppl 1):S43-S46.
15. Faderl S, Jeha S, Kantarjian HM: The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003; 98: 1337-1354.
16. Stirewalt DL, Guthrie KA, Beppu L, Bryant EM, Doney K, Gooley T, Appelbaum FR, Radich JP: Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant 2003; 9: 206-212.
17. Yoshimitsu M, Fujiwara H, Ozaki A, Hamada H, Matsushita K, Arima N, Tei C: Case of a patient with Philadelphia-chromosomepositive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. Int J Hematol 2008; 88: 331-335.
18. Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R: Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia- positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res 2009; 33: 174-177.
19. Merante S, Colombo AA, Calatroni S, Rocca B, Boni M, Bernasconi P, Bonvini L, Soverini S, Alessandrino EP: Nilotinib restores longterm full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. Bone Marrow Transplant 2009; 44: 263-264.
20. Giles FJ, O'Dwyer M, Swords R: Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1698-1707.
21. Czyz A, Lewandowski K, Kroll R, Komarnicki M: Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion. Med Oncol 2009, E-pub ahead of print.
22. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth- Hansen H, Hoglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K: Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398-1405.
23. Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, Gotz M, Guillaume P, Dohner H, Bunjes D, Schmitt M: Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 2008; 36: 1297-1308.
24. Cortes J: Central nervous system involvement in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001; 15: 145-162.
25. Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, Frank - lin IM, Tallman MS, Cook L, Buck G, Durrant IJ, Rowe JM, Goldstone AH: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: re - sults from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 2006; 108: 465-472.
26. Plosker GL, Robinson DM: Nilotinib. Drugs 2008; 68: 449-459; discussion 460-461.